Peritoneal Karsinomatoz için Komplet Sitoredüksiyon Yapılan Hastalarda Erken Morbidite ve Mortaliteyi Etkileyen Faktörler

Year 2022, Volume: 12 Issue: 3, 510 - 517, 29.09.2022

Yigit Mehmet Ozgun Volkan Öter Muhammet Kadri Çolakoğlu Erol Pişkin Osman Aydın Erdal Bostanci

https://doi.org/10.31832/smj.981215

Abstract

Amaç: Sitoredüktif cerrahi ve hipertermik intraperitoneal kemoterapi uygulaması, peritoneal karsinomatoz tedavisinde seçilmiş hastalarda kullanılan kombine tedavi yöntemidir.
Materyal ve Methot: Çalışmamızda orijini farklı tümörlerin peritoneal metastazlarına bağlı olarak Sitoredüktif Cerrahi ve hipertermik intraperitoneal kemoterapi uygulanan hastalarda erken komplikasyonların gelişimini ve komplikasyonların erken evrelerini etkileyen faktörleri araştırdık.
Hastanemizde 2014-2019 yılları arasında periton metastazı nedeniyle ameliyat edilen 76 hastanın tıbbi kayıtları retrospektif olarak değerlendirildi. Çalışmaya sadece tam sitoredüksiyon (CC/0) uygulanan 61 hasta dahil edildi.
Bulgular: Periton Kanseri İndeksi (PKİ) ve operasyon süresinin majör komplikasyon gelişimi için bağımsız risk faktörleri olduğu bulundu. Majör komplikasyon gelişimi açısından ameliyat süresi 7 saat ve Periton Kanseri İndeksi kesme değeri sırasıyla 10 saat olarak bulundu.
Sonuç: Çalışmamızda, CC/0 uygulanan hastalarda PKİ'nin ondan fazla olması ve ameliyat süresinin 7 saatten fazla sürmesinin majör komplikasyonları ve mortaliteyi artıran neden olduğunu gösterdik. CC / 0 rezeksiyonu yapmak için her türlü çaba gösterilmelidir, ancak PKG'si 10'un üzerinde olan hastalarda ve operasyon süresini 7 saatin üzerine uzatırken daha fazla özen gösterilmelidir. Bu hastalarda postoperatif komplikasyonlar perioperatif mortaliteyi artırarak erken rekürrens ve kısa sağkalıma neden olur.

Keywords

komplet sitoredüksiyon, hipertermik intraperitoneal kemoterapi, peritoneal karsinomatoz

Factors Affecting Early Morbidity and Mortality in Patients with Complete Cytoreduction for Peritoneal Carcinomatosis

Abstract

Objective: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy practice is the combined treatment modality used in selected patients for the treatment of peritoneal carcinomatosis.
Material and Methods: In our study, we investigated the development of early complications and the factors affecting the early stages of complications in patients who underwent Cytoreductive Surgery and hyperthermic intraperitoneal chemotherapy due to peritoneal metastases of tumors of different origin.
Medical records of 76 patients who operated in our hospital for peritoneal metastasis between 2014 and 2019 evaluated retrospectively. Only 61 patients who underwent complete cytoreduction (CC/0) included in the study.
Results: Peritoneal Cancer Index and operation time found to be independent risk factors for major complication development. In terms of major complication development, operation time and Peritoneal Cancer Index cutoff value found to be 7 hours and 10 respectively.
Conclusion: We have demonstrated in our study that the fact that the PCI is higher than ten and operation time lasts more than 7 hours is the reason that increases major complications and mortality in patients undergoing CC/0. All efforts should be made to perform CC/0 resection, but more care should be taken in patients having a PCI over 10 and when extending the operation time over 7 hours. In these patients, postoperative complications increase peri-operative mortality and lead to early recurrence and short survival.

Keywords

complete cytoreduction, hyperthermic intraperitoneal chemotherapy, peritoneal carcinomatosis

References

• 1. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study J Clin Oncol. 2004;22(16):3284-92.
• 2. Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7): 617-23.
• 3. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358-63.
• 4. P H Sugarbaker. Peritonectomy procedures. Ann Surg. 1995; 221(1): 29–42.
• 5. Mizumoto A, Canbay E, Hirano M, Takao N, Matsuda T, Ichinose M et al. Morbidity an Mortality Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy at a Single Institution in Japan. Gastroenterol Res Pract. 2012;2012:836425.
• 6. Parikh R, Shah S, Dhurandhar V, Alzahrani N, Fisher OM, Arrowaili A et al. An analysis of the morbidity associated with abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Eur J Surg Oncol. 2019;45(3):394-399.
• 7. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E et al. Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Ann Surg Oncol. 2015;22(5):1570-5.
• 8. Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol. 2016;23(6):1971-9.
• 9. Elias D, Goe´re´ D, Dumont F, Honore C, Dartigues P, Stoclin A. et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Ann Surg Oncol. 2016;23(6):1971-9.
• 10. da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203(6):878-86.
• 11. Berger Y, Aycart S, Mandeli JP, Heskel M, Sarpel U, Labow DM. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Surg Oncol. 2015;24(3):264-9.
• 12. Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzì S et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014;57(7):858-68.
• 13. Mehta S, Gelli M, Agarwal D, Goéré D. Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases. Indian J Surg Oncol. 2016;7(2):225–229.
• 14. Quenet F, Elias D, Lise Roca et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7,” Journal of Clinical Oncology. 2018;36:18_suppl, LBA3503-LBA3503.
• 15. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116(24):5608-18.
• 16. Chouliaras K, Levine E, Fino N, Shen P, Votanopoulos KI. Prognostic Factors and Significance of Gastrointestinal Leak After Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2017; 24(4): 890–897.
• 17. Elias D, Gilly F, Boutitie F, Bereder JM, Mansvelt B et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63-8.
• 18. Padmanabhan N, Kumar BR, Pookunju AP, Srinivasan A, Mahajan V. Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) from a Tertiary Cancer Center in India. J Clin Diagn Res. 2015;9(6):XC09-XC13.
• 19. Deraco M, Glehen O, Helm CW, Morris DL, der Speeten KV, Sugarbaker PH, Hart JB (eds). Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. 1st Edition.Woodbury, Cine Med, 2012. 20. Kusamura S, Mingrone E, Baratti D, Balestra MR, Laterza B, Deraco M. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2012;256(2):334-41.
• 21. Goéré D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH et al. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperthermia. 2017;33(5):520-527.
• 22. Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065-71. 23. Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients. Ann Surg Oncol. 2012;19(13):4052-8.
• 24. Ihemelandu C, Sugarbaker PH. Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades. Ann Surg Oncol. 2017;24(4):898-905.
• 25. Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F et al. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol. 2018;25(6):1668-1675.
• 26. Piso P, Nedelcut SD, Rau B, Königsrainer A, Glockzin G, Ströhlein MA et al. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Ann Surg Oncol. 2019;26(1):148-154.
• 27. Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818-24.
• 28. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779-85.
• 29. Narasimhan V, Britto M, Pham T, Warrier S, Naik A, Lynch AC et al. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single- Institutional Experience. Dis Colon Rectum.2019;62(10):1195-1203.
• 30. Paul H. Sugarbaker. Peritoneal Metastases from Gastrointestinal Cancer. Current Oncology Reports. 2018;20:62.
• 31. Cardi M, Sibio S, Di Marzo F, Lefoche F, d'Agostino C, Fonsi GB et al. Prognostic Factors Influencing Infectious Complications after Cytoreductive Surgery and HIPEC: Results from a Tertiary Referral Center. Gastroenterol Res Pract. 2019 2;:2824073.
• 32. Saxena A, Yan TD, Morris DL. Critical assessment of preoperative and operative risk factors for complications after iterative peritonectomy procedures. Eur J Surg Oncol. 2010;36(3):309-14.
• 33. Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S et al. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251(1):101-6.
• 34. Simkens GA, van Oudheusden TR, Luyer MD, Nienhuijs SW, Nieuwenhuijzen GA, Rutten HJ et al. Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis; Ann Surg Oncol. 2015;22(8):2656-62.
• 35. van Slooten G, van Tinteren H. 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol. 2008;15(9):2426-32.
• 36. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM et al. Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. J Clin Oncol. 2009;10;27(5):681-5.
• 37. Glehen O, Osinsky D, Cotte E. Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures. Ann Surg Oncol. 2003;10(8):863-9.